Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Identifieur interne : 000102 ( PubMed/Checkpoint ); précédent : 000101; suivant : 000103Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Auteurs : Paola Nasta [Italie] ; Ivana Maida ; Anna Maria Cattelan ; Emanuele Pontali ; Elena Angeli ; Mariarosaria Giralda ; Gabriella Verucchi ; Antonietta Caputo ; Claudio Iannacone ; Massimo Puoti ; Giampiero CarosiSource :
- Journal of women's health (2002) ; 2015.
Descripteurs français
- Wicri :
- geographic : Italie.
English descriptors
- KwdEn :
- Adult, Aging, Antiviral Agents (administration & dosage), Antiviral Agents (therapeutic use), Coinfection (drug therapy), Drug Therapy, Combination, Female, Glucose (metabolism), HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (virology), HIV-1 (drug effects), Hepacivirus (drug effects), Hepacivirus (isolation & purification), Hepatitis C, Chronic (complications), Hepatitis C, Chronic (drug therapy), Hepatitis C, Chronic (virology), Humans, Interferon-alpha (administration & dosage), Interferon-alpha (therapeutic use), Italy, Logistic Models, Male, Middle Aged, Polyethylene Glycols (administration & dosage), Polyethylene Glycols (therapeutic use), RNA, Viral (analysis), RNA, Viral (blood), Recombinant Proteins (administration & dosage), Recombinant Proteins (therapeutic use), Ribavirin (administration & dosage), Ribavirin (therapeutic use), Time Factors, Treatment Outcome, Viral Load.
- MESH :
- chemical , administration & dosage : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- chemical , analysis : RNA, Viral.
- chemical , blood : RNA, Viral.
- chemical , metabolism : Glucose.
- chemical , therapeutic use : Antiviral Agents, Interferon-alpha, Polyethylene Glycols, Recombinant Proteins, Ribavirin.
- geographic : Italy.
- complications : HIV Infections, Hepatitis C, Chronic.
- drug effects : HIV-1, Hepacivirus.
- drug therapy : Coinfection, HIV Infections, Hepatitis C, Chronic.
- isolation & purification : Hepacivirus.
- virology : HIV Infections, Hepatitis C, Chronic.
- Adult, Aging, Drug Therapy, Combination, Female, Humans, Logistic Models, Male, Middle Aged, Time Factors, Treatment Outcome, Viral Load.
Abstract
This was a post-hoc analysis of the Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study, originally designed to document routine clinical and treatment data in HIV/HCV coinfected patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV). The aim of this study was to define the impact of several variables, such as age, glucose metabolism, and HIV viral load, on PEG-IFN/RBV treatment outcomes, in HIV/HCV coinfected women.
DOI: 10.1089/jwh.2014.4796
PubMed: 25682817
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25682817Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.</title><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name><affiliation wicri:level="1"><nlm:affiliation>1 University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital , Brescia, Italy .</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>1 University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital , Brescia</wicri:regionArea><wicri:noRegion>Brescia</wicri:noRegion></affiliation></author><author><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name></author><author><name sortKey="Cattelan, Anna Maria" sort="Cattelan, Anna Maria" uniqKey="Cattelan A" first="Anna Maria" last="Cattelan">Anna Maria Cattelan</name></author><author><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name></author><author><name sortKey="Angeli, Elena" sort="Angeli, Elena" uniqKey="Angeli E" first="Elena" last="Angeli">Elena Angeli</name></author><author><name sortKey="Giralda, Mariarosaria" sort="Giralda, Mariarosaria" uniqKey="Giralda M" first="Mariarosaria" last="Giralda">Mariarosaria Giralda</name></author><author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></author><author><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author><author><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="doi">10.1089/jwh.2014.4796</idno><idno type="RBID">pubmed:25682817</idno><idno type="pmid">25682817</idno><idno type="wicri:Area/PubMed/Corpus">000109</idno><idno type="wicri:Area/PubMed/Curation">000109</idno><idno type="wicri:Area/PubMed/Checkpoint">000102</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.</title><author><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name><affiliation wicri:level="1"><nlm:affiliation>1 University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital , Brescia, Italy .</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>1 University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital , Brescia</wicri:regionArea><wicri:noRegion>Brescia</wicri:noRegion></affiliation></author><author><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name></author><author><name sortKey="Cattelan, Anna Maria" sort="Cattelan, Anna Maria" uniqKey="Cattelan A" first="Anna Maria" last="Cattelan">Anna Maria Cattelan</name></author><author><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name></author><author><name sortKey="Angeli, Elena" sort="Angeli, Elena" uniqKey="Angeli E" first="Elena" last="Angeli">Elena Angeli</name></author><author><name sortKey="Giralda, Mariarosaria" sort="Giralda, Mariarosaria" uniqKey="Giralda M" first="Mariarosaria" last="Giralda">Mariarosaria Giralda</name></author><author><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></author><author><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name></author><author><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name></author><author><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name></author><author><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name></author></analytic><series><title level="j">Journal of women's health (2002)</title><idno type="e-ISSN">1931-843X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aging</term><term>Antiviral Agents (administration & dosage)</term><term>Antiviral Agents (therapeutic use)</term><term>Coinfection (drug therapy)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Glucose (metabolism)</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (virology)</term><term>HIV-1 (drug effects)</term><term>Hepacivirus (drug effects)</term><term>Hepacivirus (isolation & purification)</term><term>Hepatitis C, Chronic (complications)</term><term>Hepatitis C, Chronic (drug therapy)</term><term>Hepatitis C, Chronic (virology)</term><term>Humans</term><term>Interferon-alpha (administration & dosage)</term><term>Interferon-alpha (therapeutic use)</term><term>Italy</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Polyethylene Glycols (administration & dosage)</term><term>Polyethylene Glycols (therapeutic use)</term><term>RNA, Viral (analysis)</term><term>RNA, Viral (blood)</term><term>Recombinant Proteins (administration & dosage)</term><term>Recombinant Proteins (therapeutic use)</term><term>Ribavirin (administration & dosage)</term><term>Ribavirin (therapeutic use)</term><term>Time Factors</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>RNA, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Glucose</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-alpha</term><term>Polyethylene Glycols</term><term>Recombinant Proteins</term><term>Ribavirin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Italy</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coinfection</term><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Hepacivirus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term><term>Hepatitis C, Chronic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aging</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Time Factors</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Italie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This was a post-hoc analysis of the Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study, originally designed to document routine clinical and treatment data in HIV/HCV coinfected patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV). The aim of this study was to define the impact of several variables, such as age, glucose metabolism, and HIV viral load, on PEG-IFN/RBV treatment outcomes, in HIV/HCV coinfected women.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25682817</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>16</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-843X</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of women's health (2002)</Title><ISOAbbreviation>J Womens Health (Larchmt)</ISOAbbreviation></Journal><ArticleTitle>Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.</ArticleTitle><Pagination><MedlinePgn>159-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/jwh.2014.4796</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This was a post-hoc analysis of the Optimized Pegylated interferons Efficacy and anti-Retroviral Approach (OPERA) study, originally designed to document routine clinical and treatment data in HIV/HCV coinfected patients treated with pegylated interferon/ribavirin (PEG-IFN/RBV). The aim of this study was to define the impact of several variables, such as age, glucose metabolism, and HIV viral load, on PEG-IFN/RBV treatment outcomes, in HIV/HCV coinfected women.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Female subjects from the OPERA database were retrospectively evaluated and factors associated with sustained virological response (SVR) were assessed and compared to the male population by logistic regression analysis. At baseline, clinical and demographic data were collected. Patients were then administered with PEG-IFN/RBV therapy for 48 weeks. After a 24-week follow-up period, SVR was evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 1523 patients were enrolled in 98 centers across Italy, 1284 of whom were IFN therapy naïve and were included in the post-hoc analysis. In the female group, factors associated with SVR were the presence of HCV genotype 2,3 (adjusted odds ratio [AOR]=6.87, p<0.0001), age ≤45 years (AOR=2.61, p=0.014), ≥80% exposure to PEG-IFN (AOR=3.85, p=0.019) and RBV (AOR=3.94, p=0.015) therapy. Also, increased glucose plasma level negatively correlated with SVR (AOR=0.98, p=0.066). In the male population, undetectable HIV-RNA (AOR=1.47, p=0.033) but not glucose level (AOR=1.0, p=0.95) predicted SVR.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Findings from the present study demonstrate that several factors may be predictive of SVR when pegylated interferon plus ribavirin is used (i.e., age, gender, HIV viral load and HCV genotype) that need to be carefully considered prior to therapeutic intervention, since they may hinder successful therapy. Use of PEG-IFN/RBV with novel direct antiviral agents will likely be still maintained until less expensive and effective interferon-free strategies become available.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nasta</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1 University Division of Infectious and Tropical Diseases, University of Brescia and Spedali Civili General Hospital , Brescia, Italy .</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maida</LastName><ForeName>Ivana</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Cattelan</LastName><ForeName>Anna Maria</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Pontali</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Angeli</LastName><ForeName>Elena</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Giralda</LastName><ForeName>Mariarosaria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Verucchi</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Caputo</LastName><ForeName>Antonietta</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Iannacone</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Puoti</LastName><ForeName>Massimo</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Carosi</LastName><ForeName>Giampiero</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Womens Health (Larchmt)</MedlineTA><NlmUniqueID>101159262</NlmUniqueID><ISSNLinking>1540-9996</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C100416">peginterferon alfa-2a</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C417083">peginterferon alfa-2b</NameOfSubstance></Chemical><Chemical><RegistryNumber>30IQX730WE</RegistryNumber><NameOfSubstance UI="D011092">Polyethylene Glycols</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D000375">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D060085">Coinfection</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005947">Glucose</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016174">Hepacivirus</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000302">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019698">Hepatitis C, Chronic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016898">Interferon-alpha</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007558">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011092">Polyethylene Glycols</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012367">RNA, Viral</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000032">analysis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011994">Recombinant Proteins</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012254">Ribavirin</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2015</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1089/jwh.2014.4796</ArticleId><ArticleId IdType="pubmed">25682817</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country></list><tree><noCountry><name sortKey="Angeli, Elena" sort="Angeli, Elena" uniqKey="Angeli E" first="Elena" last="Angeli">Elena Angeli</name><name sortKey="Caputo, Antonietta" sort="Caputo, Antonietta" uniqKey="Caputo A" first="Antonietta" last="Caputo">Antonietta Caputo</name><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name><name sortKey="Cattelan, Anna Maria" sort="Cattelan, Anna Maria" uniqKey="Cattelan A" first="Anna Maria" last="Cattelan">Anna Maria Cattelan</name><name sortKey="Giralda, Mariarosaria" sort="Giralda, Mariarosaria" uniqKey="Giralda M" first="Mariarosaria" last="Giralda">Mariarosaria Giralda</name><name sortKey="Iannacone, Claudio" sort="Iannacone, Claudio" uniqKey="Iannacone C" first="Claudio" last="Iannacone">Claudio Iannacone</name><name sortKey="Maida, Ivana" sort="Maida, Ivana" uniqKey="Maida I" first="Ivana" last="Maida">Ivana Maida</name><name sortKey="Pontali, Emanuele" sort="Pontali, Emanuele" uniqKey="Pontali E" first="Emanuele" last="Pontali">Emanuele Pontali</name><name sortKey="Puoti, Massimo" sort="Puoti, Massimo" uniqKey="Puoti M" first="Massimo" last="Puoti">Massimo Puoti</name><name sortKey="Verucchi, Gabriella" sort="Verucchi, Gabriella" uniqKey="Verucchi G" first="Gabriella" last="Verucchi">Gabriella Verucchi</name></noCountry><country name="Italie"><noRegion><name sortKey="Nasta, Paola" sort="Nasta, Paola" uniqKey="Nasta P" first="Paola" last="Nasta">Paola Nasta</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000102 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000102 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25682817
|texte= Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25682817" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |